RLN1 and neoplasm: In tumor models, gene delivery of RLN-1 promoted the infiltration of cytotoxic and antigen-presenting immune cells (CD8+ T cells, dendritic cells, NK cells) and simultaneously reduced Tregs, effectively shifting the tumor microenvironment toward an anti-tumor, immunostimulatory phenotype [8,92].